FI940098A - Menetelmiä liikehermotautien hoitamiseksi käyttäen BDNF/NT-3/NGF -molekyyliperheen jäseniä - Google Patents

Menetelmiä liikehermotautien hoitamiseksi käyttäen BDNF/NT-3/NGF -molekyyliperheen jäseniä Download PDF

Info

Publication number
FI940098A
FI940098A FI940098A FI940098A FI940098A FI 940098 A FI940098 A FI 940098A FI 940098 A FI940098 A FI 940098A FI 940098 A FI940098 A FI 940098A FI 940098 A FI940098 A FI 940098A
Authority
FI
Finland
Prior art keywords
bdnf
treatment
molecules
members
methods
Prior art date
Application number
FI940098A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI940098A0 (fi
Inventor
Vivien Wong
Czeslaw Radziejewski
Peter Distefano
Original Assignee
Regeneron Pharma
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Max Planck Gesellschaft filed Critical Regeneron Pharma
Publication of FI940098A0 publication Critical patent/FI940098A0/fi
Publication of FI940098A publication Critical patent/FI940098A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Physical Water Treatments (AREA)
  • Water Treatment By Electricity Or Magnetism (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Water Treatment By Sorption (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FI940098A 1991-07-10 1994-01-10 Menetelmiä liikehermotautien hoitamiseksi käyttäen BDNF/NT-3/NGF -molekyyliperheen jäseniä FI940098A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72770491A 1991-07-10 1991-07-10
PCT/US1992/004228 WO1993001300A1 (en) 1991-07-10 1992-05-19 Methods of treatment of motor neuron diseases using members of the bdnf/nt-3/ngf family of molecules

Publications (2)

Publication Number Publication Date
FI940098A0 FI940098A0 (fi) 1994-01-10
FI940098A true FI940098A (fi) 1994-03-10

Family

ID=24923677

Family Applications (1)

Application Number Title Priority Date Filing Date
FI940098A FI940098A (fi) 1991-07-10 1994-01-10 Menetelmiä liikehermotautien hoitamiseksi käyttäen BDNF/NT-3/NGF -molekyyliperheen jäseniä

Country Status (20)

Country Link
EP (2) EP0593516B1 (de)
JP (1) JPH06509094A (de)
CN (1) CN1065768C (de)
AT (1) ATE202939T1 (de)
AU (2) AU675409B2 (de)
CA (1) CA2113083A1 (de)
DE (1) DE69231930T2 (de)
DK (1) DK0593516T3 (de)
ES (1) ES2157903T3 (de)
FI (1) FI940098A (de)
GR (1) GR3036776T3 (de)
HU (1) HUT70275A (de)
IE (1) IE921602A1 (de)
IL (1) IL101928A0 (de)
NO (1) NO940084L (de)
PT (1) PT100501A (de)
RU (1) RU94016525A (de)
SK (1) SK2694A3 (de)
WO (1) WO1993001300A1 (de)
ZA (1) ZA923639B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4535993A (en) * 1992-06-12 1994-01-04 Regeneron Pharmaceuticals, Inc. Therapeutic and diagnostic methods based on neurotrophin-4 expression
FR2717496B1 (fr) * 1994-03-18 1996-04-12 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
CN1112215C (zh) * 1999-12-28 2003-06-25 潘晓东 神经生长因子在治疗有机溶剂中毒性周围神经病中的用途
AU5945301A (en) * 2000-05-05 2001-11-20 Res Foundation Of City Univers Methods for stimulating nervous system regeneration and repair by regulating arginase i and polyamine synthesis
EP2913393B8 (de) * 2004-11-17 2020-02-26 Seneca Biopharma, Inc. Transplantation menschlicher Nervenzellen zur Behandlung neurodegenerativer Erkrankungen
WO2008156418A1 (en) * 2007-06-19 2008-12-24 Astrazeneca Ab A method for screening or diagnosis of postpolio syndrome and fibromyalgia
CA2695997C (en) * 2007-08-10 2016-11-22 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human nerve growth factor
WO2014111525A2 (en) 2013-01-18 2014-07-24 Anaxomics Biotech, Sl New combination therapies for treating nervous system diseases
US10349890B2 (en) 2015-06-26 2019-07-16 C. R. Bard, Inc. Connector interface for ECG-based catheter positioning system
WO2023164311A2 (en) * 2022-02-28 2023-08-31 Bioincept, Llc Compositions and methods of treating amyotrophic lateral sclerosis (als) and related disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923696A (en) * 1987-05-04 1990-05-08 Baylor College Of Medicine Method to prepare a neurotrophic composition
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
IL95511A (en) * 1989-08-30 2000-10-31 Max Planck Gesellschaft Neurotrophin-3 a novel neurotrophic factor related to nerve growth and brain derived neurotrophic factor
IE903130A1 (en) * 1989-09-15 1991-03-27 Regeneron Pharma Ciliary neurotrophic factor

Also Published As

Publication number Publication date
SK2694A3 (en) 1995-02-08
DK0593516T3 (da) 2001-09-17
CN1065768C (zh) 2001-05-16
EP0755682A1 (de) 1997-01-29
ZA923639B (en) 1993-02-24
AU675409B2 (en) 1997-02-06
DE69231930D1 (de) 2001-08-16
IE921602A1 (en) 1993-01-13
HU9400063D0 (en) 1994-06-28
CA2113083A1 (en) 1993-01-21
CN1071585A (zh) 1993-05-05
NO940084D0 (no) 1994-01-10
EP0593516B1 (de) 2001-07-11
WO1993001300A1 (en) 1993-01-21
RU94016525A (ru) 1996-06-10
AU7067696A (en) 1997-01-16
DE69231930T2 (de) 2002-04-11
AU2009592A (en) 1993-02-11
HUT70275A (en) 1995-09-28
FI940098A0 (fi) 1994-01-10
IL101928A0 (en) 1992-12-30
ATE202939T1 (de) 2001-07-15
EP0593516A1 (de) 1994-04-27
NO940084L (no) 1994-03-08
PT100501A (pt) 1993-09-30
GR3036776T3 (en) 2002-01-31
EP0593516A4 (de) 1995-01-18
JPH06509094A (ja) 1994-10-13
ES2157903T3 (es) 2001-09-01

Similar Documents

Publication Publication Date Title
FI940098A (fi) Menetelmiä liikehermotautien hoitamiseksi käyttäen BDNF/NT-3/NGF -molekyyliperheen jäseniä
NO951592L (no) Fremgangsmåte for fremstilling av et transdermalt terapeutisk system
FI108146B (fi) Biologisesti aktiivisten, neurotrofisten NGF/BDNF-sarjan yhdistelmäproteiinien valmistus
ATE88900T1 (de) Konjugate von interferon alpha mit immunglobulinen.
AU6909091A (en) Neurologic agents for nasal administration to the brain
ATE213411T1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
DE69033703D1 (de) Nichtglykosyliertes fgf-4 und dieses enthaltende präparate
DE3770465D1 (de) Verwendung von zinn-protoporphyrin und zinn-mesoporphyrin zur herstellung eines arzneimittels fuer die behandlung von psoriasis.
EE03017B1 (et) Kõrge eriaktiivsusega ja teraapiliseks kasutamiseks sobiv vere XI hüübimisteguri kontsentraat ning meetod selle saamiseks
AU7426487A (en) Method of treating depression using d-fenfluramine
Gordon The relationship between language and behaviour.
MD1716B2 (en) Use of melatonin for treatment of patients dependent on benzodiazepine
Metter et al. Theoretical, Clinical, Research, and Ethical Constraints of the Eye Movement Desensitization Reprocessing Technique.
Aurela A systematic storytelling therapy.
Bogdanov et al. Methods for the restoration of motor functions in patients with acute and early recovery periods of cerebral stroke
Semke Feasibility of pathogenetic therapy for hysteria
Goldenring Comments on Ethical Protocol
ROBINSON Comments on Ethical Protocol
RU93008692A (ru) Способ рефлексотерапии
UA20012A (uk) Спосіб лікуваhhя постекстракційhої запальhої ексудативhої реакції у хворих hа катаракту

Legal Events

Date Code Title Description
FD Application lapsed